Drugs / Amgen 386
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01290263 | Dec 2010 → Jul 2015 | glioblastoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amgen 386 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01290263 ↗ |
| Route | Intravenous | “AMG 386 will be administered intravenously” NCT01290263 ↗ |